NEWS

Press Releases

Human Longevity, Inc. Announces Executive Leadership Changes; Co-Founder J. Craig Venter, Ph.D. is Reappointed as CEO

Leadership Transitions Underscore Renewed Concentration to Deliver Health Nucleus as Superior, Comprehensive Product to Revolutionize Healthcare

(SAN DIEGO, CA)—December 1, 2017—Human Longevity, Inc. (HLI), the genomics-based, health intelligence company, announced today that following the company’s recent Board of Directors meeting, J. Craig Venter, Ph.D., has been reappointed as Chief Executive Officer replacing Cynthia Collins. Saturnino (Nino) Fanlo, who currently serves as HLI’s Chief Financial Officer, has also been named Chief Operating Officer.  The company and board thank Collins for her service at HLI over the last year and wish her the very best in her future endeavors.

The company is streamlining its efforts to focus on the Health Nucleus platform, the clinical research arm of HLI designed for early screening and detection of major diseases. Health Nucleus will remain the premier public-facing center to collect, analyze and act on pre-symptomatic health data, providing clients and physicians personalized insights to optimize health, help reduce risks and enable longer, healthier lives.

“Since our inception, HLI has pursued the applications of pioneering genomics, advanced imaging and robust machine learning to generate a more insightful picture of human health than available anywhere else, and I am proud of the impact we’ve had on lives of our clients to date,” said Dr. Venter. “We are at a pivotal point where refocusing our efforts and our strong team will allow us to continue to drive this positive impact on health more broadly.”

About Human Longevity, Inc™

Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business focus includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com.

Media Contact

Heather Kowalski
hkowalski@humanlongevity.com
858-361-0466

Media Resources

HLI Fact Sheet

Tweets

NEWS

Press Releases

Researchers from Human Longevity, Inc. Use Whole Genome Sequence Data and Machine Learning to Identify Individuals Through Face and Other Physical Trait Prediction

(SAN DIEGO, CA)—September 5, 2017—Researchers from Human Longevity, Inc. (HLI) have published a study in which individual faces and other physical traits were predicted using whole genome sequencing data and machine learning. This work, from lead author Christoph Lippert, Ph.D. and senior author J. Craig Venter, Ph.D., was published in the journal Proceedings from the National Academy of Sciences (PNAS).

The authors believe that, while the study offers novel approaches for forensics, the work has serious implications for data privacy, deidentification and adequately informed consent. The team concludes that much more public deliberation is needed as more and more genomes are generated and placed in public databases.

For the IRB approved study, 1,061 ethnically diverse people ranging in age from 18 to 82 participated by having their genomes sequenced to an average depth of at least 30x. Researchers also collected phenotype data in the form of 3D facial images, voice samples, eye and skin color, age, height, and weight.

The team predicted eye color, skin color and sex with high accuracy, but other more complex genetic traits proved more difficult. The team believes their predictive models are sound, but that large cohorts are needed to make prediction more robust. The team also developed a machine learning algorithm called a maximum entropy algorithm, which had novelty in that it found an optimal combination of all predictive models to match whole-genome sequencing data with phenotypic and demographic data and enabled the correct identification of, on average, 8 out of 10 participants of diverse ethnicity, and 5 out of 10 African American or European participants.

Venter, HLI’s co-founder, executive chairman and head of scientific strategy, commented, “We set out to do this study to prove that your genome codes for everything that makes you, you. This is clearly a proof of concept with a limited cohort but we believe that as we increase the numbers of people in this study and in the HLI database to hundreds of thousands we will be able to accurately predict all that can be predicted from individuals’ genomes.”

He added, “We are also concerned that the public and the research community at large are not adequately focused on the need for better safeguards and policies for individual privacy in the genomics era and are urging more analysis, better technical solutions, and continued discussion.”

Lippert, data scientist at HLI, added, “This study shows the potential of imaging technologies to screen the traits of large numbers of individuals. Machine learning enables fully automated data interpretation and plays a crucial role in scientific discovery.”

Article #17-11125: “Identification of individuals by trait prediction using whole genome sequencing data,” Lippert et al. 

About Human Longevity, Inc.™

Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.

Media Contact

Heather Kowalski, hkowalski@humanlongevity.com, 858-361-0466

Media Contact

Heather Kowalski
hkowalski@humanlongevity.com
858-361-0466

Media Resources

HLI Fact Sheet

Tweets

NEWS

Press Releases

Human Longevity, Inc. Researchers Develop New Algorithm to Rapidly and Accurately Predict HLA Types Using Illumina Next Generation Sequencing Technology

(SAN DIEGO, CA)—July 3, 2017—Researchers from Human Longevity, Inc. (HLI) have developed a new algorithm called xHLA to rapidly and accurately determine the sequence of the human leukocyte antigen (HLA) gene region from 30x whole genome sequencing using Illumina HiSeq X10 and NovaSeq sequencing technology. This work was published by lead author Chao Xie, Ph.D. and senior author J. Craig Venter, Ph.D., in the journal Proceedings from the National Academy of Sciences (PNAS) early online edition.

The HLA region, located on chromosome 6, is one of the most diverse regions in the human genome with thousands of alleles present in the human population. The HLA complex is responsible for regulation of the human immune system and thus plays an important role in diseases of autoimmunity (such as rheumatoid arthritis), cancer, organ transplant compatibility, allergic reactions and response to vaccines.

Since HLA gene regions have a high degree of DNA sequence similarities it has been difficult to accurately predict HLA type using whole genome sequencing technologies. Instead, HLA typing has been done through more cumbersome serotyping and targeted sequencing, costing hundreds of dollars per test. Given HLI’s expertise in complete and accurate whole genome sequencing, machine learning and other informatic areas, the HLI-led team set out to develop a new tool, xHLA, to see if it could indeed be used with current generation sequencing technology for more precise and rapid HLA typing. They also wanted to compare xHLA to current HLA typing methods on the market.

The team tested xHLA against seven other HLA typing methods using three whole genome and three whole exome public datasets and showed that in all cases xHLA outperformed the other tests. The xHLA’s runtime was approximately 3 minutes for each 30x whole genome sample compared to 15 minutes to 5 hours for the other algorithms. One of the differentiators of xHLA is that it uses protein level sequence alignment which results in a more comprehensive alignment matrix giving higher accuracy than other methods.

The team concluded that this new tool should enable rapid and accurate HLA typing for any individual who has their genome sequenced by HLI. HLI currently offers physician ordered whole genome sequencing as a product, HLIQ Whole Genome and through the suite of Health Nucleus products which are: Health Nucleus Platinum, Health NucleusX Gold (HNX Gold) and Health NucleusX (HNX). In one whole genome sequence test HLI can offer screening for genes and variants proposed by the American College of Medical Genetics and Genomics (ACMG), pharmacogenetic testing, inherited cancer testing, carrier screening and now, rapid and accurate HLA testing.

Venter, who is HLI’s co-founder, executive chairman and head of scientific strategy, commented, “This paper is proof of the power of informatics and the need for complete and accurate clinical grade genomic sequencing to solve important scientific and clinical issues. The xHLA algorithm should enable seamless, accurate and rapid HLA typing for all genomic sequencing done today. HLI clients can get their HLA type as a part of their genome report, something that no other center can currently offer.”

In addition to researchers from HLI, scientists from Center for International Blood and Marrow Transplant Research, Minneapolis, MN, the J. Craig Venter Institute, La Jolla, CA; and the Department of Pathology, University of California, San Diego, La Jolla, CA all participated in this work. 

About Human Longevity, Inc.™

Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.

Media Contact

Heather Kowalski, hkowalski@humanlongevity.com, 858-361-0466

Media Contact

Heather Kowalski
hkowalski@humanlongevity.com
858-361-0466

Media Resources

HLI Fact Sheet

Tweets

NEWS

Press Releases

Human Longevity, Inc. Announces Agreement with Merck KGaA, Darmstadt, Germany to Engage in Cancer Biomarker Discovery in Advanced Melanoma

(SAN DIEGO, CA)—June 15, 2017—Human Longevity, Inc. (HLI), the genomics-powered, health intelligence company, announced today that the company has signed an agreement with Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, with the goal of pioneering the application of advanced genomics and expert analysis with machine learning to transform drug development and medical use of next generation therapeutics. As part of the agreement, the companies have started a joint pilot project to identify treatment response biomarker signatures in patients with advanced melanoma. Financial terms of the deal were not disclosed.

Cindy Collins, HLI CEO said, “Our agreement with Merck KGaA, Darmstadt, Germany will enable us to work together to discover novel insights that improve patient survival in melanoma, the deadliest form of skin cancer. With more than 230,000 new cases of melanoma diagnosed worldwide each year, and rates on the rise for the last 30 years, we believe our first pilot project is of great importance for society and look forward to working with Merck KGaA, Darmstadt, Germany to impact the treatment of melanoma.”

In the pilot project, Merck KGaA, Darmstadt, Germany and HLI are working together to identify treatment response biomarkers in patients with locally advanced or metastatic NRAS mutated cutaneous melanoma that preferentially respond to Merck KGaA Darmstadt, Germany’s MEK1/2 inhibitor, pimasertib. To enable this goal, HLI is generating genomic sequencing data from clinical trial participants’ tumor and germline and utilizing its machine learning and analytical tools and expertise to interpret and analyze this data in the context of survival and other clinical data.

HLI is building the world’s largest database of genomic, phenotypic, and clinical information. HLI has sequenced approximately 40,000 high-quality genomes and is building an unparalleled database of genomic and phenotypic integrated health records. HLI’s customers include pharmaceutical and biotechnology companies, life insurance companies, large academic medical centers, physicians and individuals.

About Human Longevity, Inc™

Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.

Media Contact

Heather Kowalski, hkowalski@humanlongevity.com, 858-361-0466

Media Contact

Heather Kowalski
hkowalski@humanlongevity.com
858-361-0466

Media Resources

HLI Fact Sheet

Tweets

NEWS

Press Releases

Saturnino (Nino) Fanlo Joins Human Longevity, Inc. as Chief Financial Officer

Financial Industry Leader Brings 30 Years of Experience Leading Public, Private Companies; Raising Billions in Financing Rounds

(SAN DIEGO, CA)—May 25, 2017—Human Longevity, Inc. (HLI), the genomics-based, health intelligence company, announced today that Saturnino (Nino) Fanlo will be joining the company as Chief Financial Officer, reporting to CEO Cynthia Collins. Fanlo brings decades of financial services acumen and strategic leadership to the role at HLI and will be instrumental in helping guide the company as it expands and strengthens commercialization and operations.

“Nino’s 30 years of financial services leadership especially his success in the fintech arena make him the ideal CFO for HLI,” said Collins. “Our company is poised for commercial success and I’m eager to have Nino as a key member of the team to ensure we remain laser focused on our goal of creating health intelligence in the healthcare market.”

“Joining Cindy, Craig Venter and the rest of the strong management team at HLI is a genuine honor. The technologies and products that HLI has created to positively impact the healthcare landscape are remarkable and the chance to contribute my skills and experience to this company is an exhilarating challenge,” said Fanlo.

Fanlo joins HLI from Social Finance, Inc. (Sofi), the largest and fastest growing online lender, where he served as President and Chief Financial Officer. Fanlo was a key leader at Sofi who worked hand in hand with the CEO and founder to design and build capital markets, loan sale, finance, and credit and loan operations there. He led five successful capital raises for more than $1.9 billion and moved the company from an $8 million to a $4.3 billion valuation in under five years. He was also a key architect of many of Sofi’s unique financial products.

Prior to Sofi, Fanlo held a series of high level leadership roles in well-respected financial services firms. Before Sofi, he was a Senior Advisor at Golden Gate Capital where he helped to develop their $1 billion Credit Opportunity Fund and the $200 million Public Equity Fund. For 5 years, he served as the CEO of KKR Financial, and CIO and Partner of KKR Asset Management where was responsible for capital raising, investment policy, portfolio selection and management, recruiting and development, and investor communications. He led the initial public offering of KKR Financial after just nine months of establishing this spinout. He also raised $ 4 billion in equity capital and $10 billion of permanent investment capital.

Prior to that he also served as Executive Vice President and Treasurer of Wells Fargo & Co., where he was responsible for funding, capital and investment portfolio including cash management and liquidity operations. Other roles in his career include leadership positions with Goldman, Sachs & Co., Australian Capital Equity, and First Boston Corporation.

Fanlo received his Bachelor of Economics from Haverford College, Haverford, PA.

About Human Longevity, Inc™

Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.

Media Contact

Heather Kowalski, hkowalski@humanlongevity.com, 858-361-0466

Media Contact

Heather Kowalski
hkowalski@humanlongevity.com
858-361-0466

Media Resources

HLI Fact Sheet

Tweets

NEWS

Press Releases

Human Longevity, Inc. Launches Pilot Program, Health Nucleus X

Offering Includes Whole Genome Sequencing and Full Body MRI to Give Insight into Cancer, Cardiovascular, Metabolic and Neurological Disease Risk

(SAN DIEGO, CA)—May 11, 2017—Human Longevity, Inc. (HLI), the genomics-based, health intelligence company, today announced a pilot program, Health Nucleus X (HNX) as part of the company’s Health Nucleus clinical research program, that offers individuals and their physicians proactive access to genomics and advanced MRI giving rapid insights into their health.

HNX focuses on core testing areas of whole genome sequencing and advanced whole body, 3T, non-contrast MRI and takes about three hours. The pilot is being offered in the Health Nucleus facility in La Jolla, California from May 1 through June 30, 2017 for an introductory price of $7,500. The company expects to open free standing HNX facilities in other cities.

The company also offers its more comprehensive Health Nucleus Platinum program which is a full eight-hour day of health testing that includes the two modalities from HNX along with others such as CT scans, echocardiogram, EKG, and a more complete battery of metabolic and lab testing. To date 570 people have participated in the HN Platinum experience with nearly 40% having had significant findings which were found at an early stage. Health Nucleus and HNX both provide a new approach to provide clients with personalized health insights into cancer, neurological, metabolic and cardiovascular disease risk.

“Building on the success and important health findings from our Health Nucleus Platinum experience, we are pleased to pilot Health Nucleus X which we believe will enable more people to experience the health insights that come from this advanced testing,” said Cynthia Collins, CEO, HLI. “Our aim with the Health Nucleus and HNX is to give individuals and their physicians the data to create integrated, personalized and proactive health plans for their future.”

Specifically, the HNX experience includes:

  • Advanced whole body and brain MRI scan
  • Whole genome sequence analysis
  • A few specific laboratory tests
  • An in-depth report with full review of the results
  • Microbiome test (included for an additional $500)

Health Nucleus Platinum and HNX give clients and their physicians access to the latest MRI technology and use advanced protocols with review by expert clinicians all of which is not routinely available anywhere else. The Health Nucleus team of clinicians and scientists review individual findings and integrate these with the genome sequencing to provide personalized health insights. The whole genome testing can also give insights into which pharmaceuticals may work better for individuals, carrier status for family planning decisions, along with ancestry and personal traits.

About Human Longevity, Inc™

Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.

Media Contacts

Heather Kowalski, hkowalski@humanlongevity.com, 858-361-0466

Katie McCormick Lelyveld, kml@humanlongevity.com

Media Contact

Heather Kowalski
hkowalski@humanlongevity.com
858-361-0466

Media Resources

HLI Fact Sheet

Tweets

NEWS

Press Releases

Human Longevity, Inc. Enhances Senior Leadership Team, Making Key Hires to Strengthen Commercialization and Operations

Travis Lacey is Chief Corporate Development Officer, Dale Gordon is Chief Commercialization Officer, Gary G. Altman, Ph.D., joins as Chief Operating Officer and Steven Ness, D.O., is Head of Client Services

(SAN DIEGO, CA) May 2, 2017– Human Longevity, Inc. (HLI) the genomics-powered, health intelligence company, announced today that several new senior staff have been hired to lead and continue to develop the company’s growing portfolio of genomic based, CLIA-validated products and associated business strategy and operations.

These key additions are: Travis Lacey, Chief Corporate Development Officer; Dale Gordon, Chief Commercial Officer; Gary G. Altman, Ph.D., Chief Operating Officer, who will all report to HLI CEO, Cynthia Collins – and Steven Ness, D.O., client services strategist who reports to Dale Gordon.

Collins stated, “Over the last months HLI has launched several important products including our whole genome sequencing product to the insurance industry, our suite of oncology products, and we have continued to grow the HLI database of genomic and phenotypic data. We are at a pivotal point in the evolution of HLI and I am pleased to welcome Travis, Dale, Gary and Steve—all seasoned business leaders—to help me build on the sound science foundation and revolutionary technology at HLI.”

Travis Lacey – Chief Corporate Development Officer

Travis Lacey has more than 20 years of experience in healthcare across functions including investment banking, business development, and operations. During his career, he has successfully led over fifty mergers and acquisitions and financing transactions with significant domain and functional expertise across the healthcare landscape, including pharma, devices and healthcare services.

Lacey joined HLI from GE Healthcare where he was managing director leading the divestiture practice and portfolio optimization across the $18B GE Healthcare platform. Prior to GE Healthcare, Lacey spent nine years in healthcare investment banking at Jefferies and Co., Inc. and Robert W. Baird & Co., Inc. where he was responsible for sourcing and leading merger and acquisitions and financing transactions. Prior to that, he spent the first ten years of his career at Abbott Laboratories where he held multiple positions across operations, manufacturing technology and quality.

Lacey received his Bachelor of Science in Statistics from University of Tennessee, Knoxville and his MBA from Northwestern University’s Kellogg School of Management.

Dale Gordon – Chief Commercial Officer

Dale Gordon serves as chief commercial officer at Human Longevity. Prior to joining HLI, Gordon was most recently with GE Healthcare as the general manager of account management. There he was focused on the development and execution of commercial account management strategies, driving profitable growth and an improved customer experience across GE’s Lab, Cell Therapy and Bioprocess businesses.

Before taking his position at GE, he had a long career at EMD Millipore, now MilliporeSigma and part of the Merck KGaA Group. There he served as head of regional (commercial) marketing in the Americas, responsible for developing and executing the regional marketing strategy across the multiplex and cytometry, lab water, separation and preparation, advanced analytics, life science reagents/antibodies, and biomonitoring portfolios. Other positons included head of North American sales, account management, head of global sales operations, global sales forces effectiveness manager, and area sales manager.

Gordon is a graduate of the University of Florida where he received a Bachelor of Science in Microbiology and Cell Science. He served on the board of directors at the Lab Product Association and served as chairman of their government affairs committee. He also serves on the board of directors at Small Steps for Compassion located in Tanzania, Africa.

Gary G. Altman, Ph.D. – Chief Operating Officer

Gary Altman has more than 25 years of experience in leading start-ups and global businesses from concept through commercialization. His experience includes roles as CEO, COO, VP and GM.

As co-founder and chief operating officer of a VC-backed drug discovery company, Altman raised $60M and advanced two drug candidates into human clinical trials. As general manager of a global business within a public corporation, Altman had P&L responsibility for $200M. He has initiated and led highly-productive relationships with diverse constituencies including academia, non-profits, and industry. Altman’s experience spans a broad spectrum of technologies including cell therapy, therapeutics, and diagnostics.

He holds a Ph.D. in Biochemistry and was a National Science Foundation post-doctoral fellow in the lab of Howard Temin, 1975 Nobel Laureate, at the University of Wisconsin, and served on the faculty of the MBA program at Johns Hopkins.

Steven Ness, D.O.– Client Services Lead

Steven (Steve) Ness, DO has more than 17 years of experience leading marketing, medical affairs and client services teams in the diagnostic and life sciences fields. Most recently he served as director of client services at GE Healthcare’s Clarient Diagnostics leading the department to industry-best customer service response times. Prior to joining GE, he held medical affairs and marketing positions at Quidel Corporation, Quest Diagnostics and Antech Diagnostics. In 2006 he co-founded Veterinary Diagnostics Institute, a veterinary reference laboratory, and launched the industry’s 1st canine, feline and equine biomarker for heart disease and heart failure. The test was marketed under the brand name CardioCare. Idexx Laboratories purchased the rights to this test and now sells it under the Idexx CardioPet brand name.

Ness received a Bachelor of Science in Biology from Norwich University, Military College of Vermont, and his Doctor of Osteopathic Medicine degree from University of New England. He completed a pediatric internship at Balboa Naval Hospital in San Diego, CA. He served for five years as an active duty Navy physician stationed at Camp Pendleton where he was Regimental Surgeon for the 11th Marine Corps Regiment. There he had five Navy physicians under his leadership and was responsible for the healthcare of over 3,000 active duty U.S. Marines. He deployed to Iraq in support of Operation Iraqi Freedom. Ness was honorably discharged from the Navy at the rank of Lieutenant Commander.

About Human Longevity, Inc™

Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ Whole Genome and HLIQ Oncology. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.

Media Contacts

Heather Kowalski hkowalski@humanlongevity.com, 858-361-0466
Katie McCormick Lelyveld, kml@humanlongevity.com

Media Contact

Heather Kowalski
hkowalski@humanlongevity.com
858-361-0466

Media Resources

HLI Fact Sheet

Tweets

NEWS

Press Releases

Machine Learning Visionary, David Heckerman, Joins Human Longevity, Inc. as Chief Data Scientist

SAN DIEGO, CA, March 21, 2017 – Human Longevity, Inc., the genomics–powered, health intelligence company, announced today that David Heckerman, M.D., PhD., a 25-year veteran of Microsoft, has joined the company as the Chief Data Scientist. Dr. Heckerman, who will report to J. Craig Venter, Ph.D., HLI Co-founder, Executive Chairman and head of scientific strategy, will lead an advanced analytics team at HLI’s Mountain View, CA, office to continue to tackle some of the most important challenges in the analysis of large-scale medical and genomic data.

Dr. Heckerman’s many accomplishments as a Microsoft researcher include leading the company’s first research team to focus on machine learning and produce tools such as the first content-based spam filter. Later, he led the first research team to focus on computational biology, designing a vaccine for HIV as well as many algorithms for biology and health, with increasing emphasis over time on genomics. For the last several years, Heckerman has led the Microsoft Genomics team, advancing research in genomics and computational biology and supporting Microsoft cloud services for genomics.

“We are thrilled to have David onboard because his unparalleled expertise in machine learning, technical expertise in cloud computing, and extensive applications in genomics are going to be invaluable to HLI,” said Dr. Craig Venter, HLI Co-Founder and Executive Chairman. “David encompasses all the fields that are needed for success in the new landscape of data computing for medicine.”

Throughout his roles at Microsoft, Dr. Heckerman served in a series of academic positions, including Visiting Senior Research Scientist at the Data Science Institute of Columbia University, Affiliate Professor in the Department of Biomedical Informatics and Health Education at University of Washington, and Adjunct Professor at University of California, Los Angeles (UCLA). He holds several degrees from Stanford University and UCLA, including M.D., Ph.D. and M.S. in Computer Science from Stanford, and M.S. and B.S. in Physics, and B.S in Mathematics, from UCLA. He is an ACM and AAAI fellow.

“I am excited to join HLI as I believe my experiences in machine learning, genomics, and healthcare are ideal to help HLI in its next phases of growth and commercialization,” said Dr. Heckerman. “I look forward to leading and expanding the dynamic and expert team in our Mountain View office.”

HLI is building the world’s largest database of clinical, biological and behavioral information, including comprehensive genome and phenotype content curated with our proprietary computational tools by the leading experts in the field. As part of this effort, HLI is making data from over 10,000 genomes available to researchers through our Open Search tool, generating more insight into individual genomes through their comparison with many. HLI Open Search is an efficient, rapid, interactive way to explore genomic data and subsequent variant knowledge, created by HLI via a web-based search engine.

HLI is hiring experts in computational biology, quantitative genomics, biostatistics, bioinformatics, natural language processing, and machine learning to join the team in Mountain View and engage in genomics-powered, technology-driven innovations to generate health intelligence, including our HLI database and HLI Search data analysis services. Please visit our website to find out more about these positions.

About Human Longevity, Inc.™

Human Longevity, Inc. (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize health. In addition to the HLIQ Whole Genome and HLIQ Oncology, HLI’s business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.

Media Contact

Katie McCormick Lelyveld, kml@humanlongevity.com, 858-249-7582

Media Contact

Heather Kowalski
hkowalski@humanlongevity.com
858-361-0466

Media Resources

HLI Fact Sheet

Tweets

NEWS

Press Releases

Human Longevity, Inc. and MassMutual Sign Groundbreaking Agreement to Offer HLIQ™ Whole Genome Sequencing to MassMutual’s Customers, Financial Professionals and Employees

SAN DIEGO, Calif. and SPRINGFIELD, Mass. – March 15, 2017— Human Longevity, Inc. (HLI), the genomics-based, health intelligence company and Massachusetts Mutual Life Insurance Co. (MassMutual), announced today they have signed an innovative multi-year agreement to offer HLI’s whole genome sequencing product, HLIQ Whole Genome, to eligible MassMutual customers, employees and financial professionals at a reduced price. The initiative should help enable HLI’s goal of providing up to 200,000 HLIQ Whole Genome reports.

“MassMutual has long believed that both financial and physical health are important, inextricably linked components of individual well-being,” said Gareth Ross, MassMutual’s Chief Digital and Customer Experience Officer. “Our cutting-edge agreement with HLI – which is unlike anything else in our industry – may better enable our customers, employees and financial professionals to see the benefits of a long and healthy life.”

HLIQ Whole Genome, which is ordered by a client’s physician, includes comprehensive sequencing and analysis of the individual’s whole genome. The report may give insight into health status and risk for disease, details on which pharmaceuticals may work better for individuals, carrier status for family planning decisions, along with ancestry and personal traits. Clients and their doctors will receive an electronic version of the genome report and their entire genome in a printable poster format.

HLI’s data security standards are designed to fully protect client data. MassMutual will not receive from HLI any data, including genomic data, on these policyowners, customers, employees or financial professionals. MassMutual does not pay for or otherwise subsidize the cost of the HLIQ Whole Genome. This voluntary program is available to existing MassMutual customers as of March 14, 2017.

Cynthia Collins, HLI Chief Executive Officer stated, “Current practice of medicine is reactive, focused on management of disease and costly. The HLIQ Whole Genome is one of HLI’s novel solutions to help make healthcare more predictive, proactive, and preventative. We continue to believe that genomics will play an increasingly important role across a variety of business sectors including insurance and look forward to working with MassMutual.”

HLI has developed one of the world’s largest databases, which currently has approximately 40,000 genomes and related phenotype (physical trait) data. This distinct database, combined with HLI’s proprietary tools and machine learning capabilities, may enable HLI to make new discoveries from the genome, which could lead to more novel insights for customers. Clients also have the added benefit of knowing that their genomic data is helping to enhance the overall understanding of health and disease.

The offer is available through March 14, 2018.To learn more about HLIQ Whole Genome, customers should start by visiting MassMutual’s website at www.massmutual.com/hli. More information about HLI and HLIQ Whole Genome can be found at www.humanlongevity.com.

About Human Longevity, Inc.™
Human Longevity, Inc. (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize health. In addition to the HLIQ Whole Genome and HLIQ Oncology, HLI’s business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit http://www.humanlongevity.com or http://www.healthnucleus.com.

About MassMutual

MassMutual is a leading mutual life insurance company that is run for the benefit of its members and participating policy owners. MassMutual offers a wide range of financial products and services, including life insurance, disability income insurance, long term care insurance, annuities, retirement plans and other employee benefits. For more information, visit www.massmutual.com. MassMutual Financial Group is a marketing name for Massachusetts Mutual Life Insurance Company (MassMutual) and its affiliated companies and sales representatives.

HLI Media Contacts:

Heather Kowalski hkowalski@humanlongevity.com, 858-361-0466

Katie McCormick Lelyveld, kml@humanlongevity.com, 858-249-7582

MassMutual Media Contact:

Michael McNamara, michaelmcnamara@massmutual.com, 413-744-3917

Media Contact

Heather Kowalski
hkowalski@humanlongevity.com
858-361-0466

Media Resources

HLI Fact Sheet

Tweets

NEWS

Press Releases

In Largest Whole Genome Sequence Analysis Study, Human Longevity, Inc.-Led Team Identifies Common-to-Rare Variants in the Human Blood Metabolome

The study shows the power of whole genome sequencing and analysis to uncover new variants missed in exome or genotyping arrays

(SAN DIEGO, CA)—March 6, 2017—Researchers from Human Longevity, Inc. (HLI), the genomics-based, health intelligence company, have published results from the largest whole genome sequencing and analysis of blood metabolites. They were able to link 101 new sites in the genome to 246 metabolites and uncovered 90 rare variants that led to abnormal blood levels of certain metabolites. This work extends the known world of loci affecting the metabolome and highlights the surprising fact that there are more rare variants associated with abnormal blood metabolic phenotypes in adults than previously thought.

(more…)

Media Contact

Heather Kowalski
hkowalski@humanlongevity.com
858-361-0466

Media Resources

HLI Fact Sheet

Tweets